The global primary cells market size is anticipated to reach USD 4.00 billion by 2030, growing at a CAGR of 10.39% from 2024 to 2030. The market is expected to grow due to the increased demand for monoclonal antibodies, rising cancer research, growing preference for primary human cells over cell lines, and increasing government initiatives for cell-based research.
The surge in chronic diseases globally, such as cancer and autoimmune disorders, has led to a growing demand for targeted therapies like monoclonal antibodies. The adoption of these biopharmaceuticals is on the rise as they offer an effective treatment approach by selectively targeting diseased cells while minimizing the impact on healthy ones. The production of monoclonal antibodies often involves the use of primary cells, which are cells taken directly from living organisms or tissues. Primary cells retain the genetic and phenotypic characteristics of the original tissue or organism from which they were derived, making them more authentic models for studying biological processes and producing antibodies.
Moreover, human primary cells play a crucial role in research and development in the field of cell therapy. Cell therapy involves the transplantation of cells to replace or repair damaged tissues and organs, offering promising treatment options for various diseases and conditions. Human primary cells, derived directly from living tissue, provide a more physiologically relevant model than the immortalized cell lines, making them valuable tools in cell therapy research. Donor-to-donor variability, including HLA type and CMV status, in human primary cells is important for personalized medicine approaches in cell therapy as individual differences are likely to impact treatment outcomes. Furthermore, Contract Research Organizations (CROs) specializing in primary cell derivation provide researchers access to a wide range of services related to isolating and preparing primary cells from diverse tissue sources.
This product will be delivered within 1-3 business days.
The surge in chronic diseases globally, such as cancer and autoimmune disorders, has led to a growing demand for targeted therapies like monoclonal antibodies. The adoption of these biopharmaceuticals is on the rise as they offer an effective treatment approach by selectively targeting diseased cells while minimizing the impact on healthy ones. The production of monoclonal antibodies often involves the use of primary cells, which are cells taken directly from living organisms or tissues. Primary cells retain the genetic and phenotypic characteristics of the original tissue or organism from which they were derived, making them more authentic models for studying biological processes and producing antibodies.
Moreover, human primary cells play a crucial role in research and development in the field of cell therapy. Cell therapy involves the transplantation of cells to replace or repair damaged tissues and organs, offering promising treatment options for various diseases and conditions. Human primary cells, derived directly from living tissue, provide a more physiologically relevant model than the immortalized cell lines, making them valuable tools in cell therapy research. Donor-to-donor variability, including HLA type and CMV status, in human primary cells is important for personalized medicine approaches in cell therapy as individual differences are likely to impact treatment outcomes. Furthermore, Contract Research Organizations (CROs) specializing in primary cell derivation provide researchers access to a wide range of services related to isolating and preparing primary cells from diverse tissue sources.
Primary Cells Market Report Highlights
- Human primary cells dominated the origin segment in 2023, owing to their importance in research as they closely resemble the physiological state of cells in vivo, thereby providing more biologically relevant data than immortalized cell lines.
- The hematopoietic cells type segment held the largest market share in 2023. On the other hand, skeletal and muscle cells segment is expected to grow at the highest CAGR of 12.51% from 2024 to 2030.
- In 2023, cancer research dominated the application segment and held the largest market share of 37.74%. Furthermore, the regenerative medicine segment is expected to grow at the highest CAGR over the forecast period.
- Based on end-use, the pharmaceuticals & biotechnology companies segment held the largest market share in terms of revenue in 2023.
- North America dominated the market for primary cells with a revenue share of 36.11% owing to the growing investments in the field of cancer research, cell therapies, and personalized and regenerative medicine.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Primary Cells Market Variables, Trends & Scope
Chapter 4. Primary Cells Market: Origin Estimates & Trend Analysis
Chapter 5. Primary Cells Market: Type Estimates & Trend Analysis
Chapter 6. Primary Cells Market: Application Estimates & Trend Analysis
Chapter 7. Primary Cells Market: End-use Estimates & Trend Analysis
Chapter 8. Primary Cells Market: Regional Estimates & Trend Analysis By Origin, Type, Application, End-Use.
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Thermo Fisher Scientific
- Merck KGaA
- Lonza
- Cell Biologics, Inc.
- PromoCell
- ZenBio
- STEMCELL Technologies
- AllCells
- American Type Culture Collection
- Axol Biosciences Ltd.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 120 |
Published | June 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 2.02 Billion |
Forecasted Market Value ( USD | $ 4 Billion |
Compound Annual Growth Rate | 10.3% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |